Actively Recruiting
Evaluating Arumakimig MAS825 for VEXAS Syndrome A 52-Week Randomized Study with Optional 2-Year Open-Label Extension
Led by Novartis Pharmaceuticals · Updated on 2026-10-13
120
Participants Needed
4
Research Sites
120 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the clinical effectiveness and safety of a drug called arumakimig MAS825 compared to a placebo in adults with VEXAS syndrome, a rare autoinflammatory condition linked to a mutation in the UBA1 gene. This study is a Phase 2, randomized, double-blind trial focused on participants who are also receiving glucocorticoids. The goal is to assess key disease improvements and the ability to reduce oral glucocorticoid use over 52 weeks. Participants will be randomly assigned to receive either arumakimig or placebo injections for 52 weeks while continuing glucocorticoid therapy, with the option to taper glucocorticoids after the first two weeks based on disease status. After this double-blind phase, eligible participants may enter a 2-year open-label extension to receive arumakimig until Week 156. Following the treatment periods, a 16-week safety follow-up is conducted to monitor long-term safety and tolerability. During the trial, participants will undergo assessments to measure improvements in VEXAS manifestations, glucocorticoid reduction, overall clinical response, flare-free days, and hematologic improvements. Safety will be closely monitored through adverse event tracking up to Week 172. Participants will also complete questionnaires about their disease status. The total participation duration can extend up to approximately three years including treatment, extension, and follow-up periods.
CONDITIONS
Brief Title
A 52-Week Study Evaluating the Efficacy and Safety of Arumakimig (MAS825) in Participants With VEXAS Followed by Open-Label Extension (OLE) Period
Research Team
N
Novartis Pharmaceuticals
N
Novartis Pharmaceuticals
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here